AA
SAGE

ALPS Advisors’s Sage Therapeutics SAGE Stock Holding History

ALPS Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-44,238
Closed -$910K – 1007
2023
Q3 		$910K Buy
44,238
+308
+0.7% +$8.89K 0.01% 488
2023
Q2 		$2.07M Buy
43,930
+4,585
+12% +$228K 0.02% 301
2023
Q1 		$1.65M Sell
39,345
-985
-2% -$42.4K 0.01% 327
2022
Q4 		$1.54M Buy
40,330
+7,884
+24% +$301K 0.01% 350
2022
Q3 		$1.27M Sell
32,446
-2,592
-7% -$100K 0.01% 394
2022
Q2 		$1.13M Sell
35,038
-25,654
-42% -$860K 0.01% 456
2022
Q1 		$2.01M Sell
60,692
-7,482
-11% -$281K 0.02% 207
2021
Q4 		$2.9M Sell
68,174
-3,904
-5% -$163K 0.03% 200
2021
Q3 		$3.19M Sell
72,078
-9,076
-11% -$416K 0.03% 212
2021
Q2 		$4.61M Buy
81,154
+76,719
+1,730% +$5.42M 0.04% 180
2021
Q1 		$332K Buy
+4,435
New +$364K ﹤0.01% 708
2017
Q4 		– Sell
-36,874
Closed -$2.3M – 878
2017
Q3 		$2.3M Buy
36,874
+3,165
+9% +$249K 0.02% 179
2017
Q2 		$2.69M Buy
33,709
+1,734
+5% +$125K 0.02% 169
2017
Q1 		$2.27M Sell
31,975
-3,741
-10% -$219K 0.02% 169
2016
Q4 		$1.82M Sell
35,716
-5,198
-13% -$245K 0.01% 182
2016
Q3 		$1.88M Sell
40,914
-4,130
-9% -$168K 0.02% 188
2016
Q2 		$1.36M Buy
45,044
+9,036
+25% +$301K 0.01% 196
2016
Q1 		$1.15M Sell
36,008
-2,013
-5% -$70.9K 0.01% 181
2015
Q4 		$2.22M Sell
38,021
-6,380
-14% -$316K 0.02% 169
2015
Q3 		$1.88M Buy
44,401
+16,267
+58% +$1M 0.02% 174
2015
Q2 		$2.05M Buy
28,134
+15,272
+119% +$982K 0.02% 167
2015
Q1 		$646K Buy
+12,862
New +$553K 0.01% 206

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's SAGE Position: Q4 2023 in Review

ALPS Advisors sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 44,238 shares — an estimated $910K sold.

ALPS Advisors first reported a position in SAGE in Q1 2015 and held it in 22 quarters. The position peaked at $4.61M in Q2 2021. 201 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

  • ALPS Advisors reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
  • ALPS Advisors sold 44,238 Sage Therapeutics shares in Q4 2023, an estimated $910K.
  • ALPS Advisors first reported a position in Sage Therapeutics in Q1 2015 and held it in 22 quarters.
  • ALPS Advisors's Sage Therapeutics position peaked at $4.61M in Q2 2021.
  • 201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.